指南与共识儿科与产科急症消化、代谢与肾脏急症

妊娠期对COVID-19的易感性分析及潜在药物筛选建议

Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
指南 / 共识 · Eur J Clin Microbiol Infect Dis · 2020-04-23
一句话结论妊娠期女性对SARS-CoV-2易感性增高,治疗需兼顾母体疗效与胎儿安全,氯喹、二甲双胍、他汀类、洛匹那韦/利托那韦、甘草酸及纳米粒介导给药等被列为值得考虑的候选药物。

本文通过综述现有文献,从妊娠期解剖、生殖内分泌及免疫变化三方面分析孕妇对病毒尤其是SARS-CoV-2的易感性,并筛查现有药物中有效且对胎儿安全的COVID-19治疗选择。妊娠期呼吸系统解剖改变使飞沫和气溶胶传播的病毒更易吸入且难以清除,感染后预后较非妊娠女性更差;生殖激素和免疫系统变化使孕妇更易感某些感染;SARS-CoV-2受体ACE2在妊娠期被证实高度增加,可能促进易感性。目前尚无COVID-19特效药,老药新用成为疫情应急手段,氯喹、二甲双胍、他汀类、洛匹那韦/利托那韦、甘草酸及纳米粒介导给药等因母胎安全性较优而值得考虑。妊娠期药物安全性研究仍存诸多不足,需开发广谱、有效且胎儿安全的药物以应对未来更多传染病。

要点

  • 妊娠期呼吸系统解剖改变使飞沫和气溶胶传播的病毒更易被吸入且难以清除,感染后预后较非妊娠女性更差。
  • 妊娠期生殖激素和免疫系统变化使孕妇更易感某些感染;ACE2作为SARS-CoV-2受体被证实在妊娠期高度增加,可能促进对SARS-CoV-2的易感性。
  • 目前尚无COVID-19特效药,老药新用成为疫情应急手段;氯喹、二甲双胍、他汀类、洛匹那韦/利托那韦、甘草酸及纳米粒介导给药等因母胎安全性较优值得考虑用于COVID-19孕妇。
  • 妊娠期药物安全性研究仍存诸多不足,需开发广谱、有效且胎儿安全的药物以应对未来更多传染病。

适用人群与场景

  • 妊娠期女性,尤其需关注对SARS-CoV-2的易感性及感染后预后较非妊娠女性更差的情况。

处置流程与药物剂量

  • 目前尚无COVID-19特效药,老药新用成为疫情应急手段;氯喹、二甲双胍、他汀类、洛匹那韦/利托那韦、甘草酸及纳米粒介导给药等因母胎安全性较优,值得考虑用于COVID-19孕妇。

研究设计与关键结果

  • 妊娠期呼吸系统解剖改变使飞沫和气溶胶传播的病毒更易被吸入且难以清除;感染后预后较非妊娠女性更差。
  • 妊娠期生殖激素和免疫系统变化使孕妇更易感某些感染;ACE2作为SARS-CoV-2受体被证实在妊娠期高度增加,可能促进对SARS-CoV-2的易感性。
  • 目前尚无COVID-19特效药,老药新用成为疫情应急手段;氯喹、二甲双胍、他汀类、洛匹那韦/利托那韦、甘草酸及纳米粒介导给药等因母胎安全性较优值得考虑用于COVID-19孕妇。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:妊娠期药物安全性研究仍存诸多不足,需开发广谱、有效且胎儿安全的药物以应对未来更多传染病。

对床旁实践的改变

  • 妊娠期女性对SARS-CoV-2易感性增高,临床选药需兼顾母体疗效与胎儿安全;氯喹、二甲双胍、他汀类、洛匹那韦/利托那韦、甘草酸及纳米粒介导给药等被作者列为母胎安全性较优、值得考虑的候选药物。
  • 作者指出妊娠期药物安全性研究仍存诸多不足,需开发广谱、有效且胎儿安全的药物以应对未来更多传染病。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future.

来源:Eur J Clin Microbiol Infect Dis,查看原文。版权归原作者所有。

参考来源

  1. Zhao X, Jiang Y, Zhao Y, et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32328850. doi:10.1007/s10096-020-03897-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。